Cover Image
市場調查報告書

日本的冠狀動脈血管閉合設備市場

Japan Market Report for Coronary Vascular Closure Devices 2018 - MedCore

出版商 iData Research Inc. 商品編碼 616039
出版日期 內容資訊 英文 675 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
日本的冠狀動脈血管閉合設備市場 Japan Market Report for Coronary Vascular Closure Devices 2018 - MedCore
出版日期: 2017年10月01日 內容資訊: 英文 675 Pages
簡介

本報告提供日本的冠狀動脈血管閉合設備市場相關調查分析,提供疾病概要,產品評估,市場分析相關的系統性資訊。

摘要整理

日本的介入心臟病學市場概要

競爭分析

市場趨勢

市場發展

對象市場

對象治療

版本履歷

第1章 調查手法

第2章 疾病概要

  • 基本結構
  • 疾病的治療和診斷
  • 患者的人口動態

第3章 產品評估

  • 產品系列
  • 法規問題和回收
  • 臨床實驗

第4章 冠狀動脈血管閉合設備市場

  • 簡介
  • 市場分析與預測
  • 促進因素及阻礙因素
    • 推動市場要素
    • 市場阻礙因素
  • 競爭市場佔有率分析

簡稱

附錄

目錄
Product Code: iDATA_JPIC18_MC_CVCD

Vascular closure devices (VCDs) are used in both the peripheral and coronary markets for minimally invasive cardiovascular therapies, which has created a large market for post-procedural VCDs. The introduction of a catheter into the arterial system, to place a stent for example, is much less traumatic for the patient than a comparable surgical intervention, with only a hole created in the artery (generally the femoral) for access. This access hole will bleed profusely if unmanaged, and therefore some form of vascular closure is required.

General Report Contents:

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

The gold standard in this market is manual compression. Although effective, this approach is wasteful of man-power, with perhaps 20 minutes to several hours of compression time required. With the general shortage of nursing labor, many hospitals are finding it cost-effective to employ VCDs to accelerate the closure process.

This report only covers the market for closure devices that were used in association with coronary procedures.

There are two types of vascular closure devices: invasive and non-invasive. Invasive devices operate by inserting a device component into the arterial hole and causing closure by various mechanisms (including sutures and collagen sponges). Non-invasive devices act at the exterior of the skin to achieve hemostasis. In addition, there are two main forms of non-invasive devices: patches and inflatable pressure bulb. For the purposes of this report, this chapter will not be broken down to separate segments.

Table of Contents

TABLE OF CONTENTS I

LIST OF FIGURES XXI

LIST OF CHARTS XXIX

EXECUTIVE SUMMARY 1

JAPAN INTERVENTIONAL CARDIOLOGY MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 4

MARKET TRENDS 7

MARKET DEVELOPMENTS 9

MARKETS INCLUDED 10

PROCEDURES INCLUDED 11

VERSION HISTORY 11

RESEARCH METHODOLOGY 12

    • Step 1: Project Initiation & Team Selection 12
    • Step 2: Prepare Data Systems and Perform Secondary Research 15
    • Step 3: Preparation for Interviews & Questionnaire Design 17
    • Step 4: Performing Primary Research 18
    • Step 5: Research Analysis: Establishing Baseline Estimates 20
    • Step 6: Market Forecasts and Analysis 21
    • Step 7: Identify Strategic Opportunities 23
    • Step 8: Final Review and Market Release 24
    • Step 9: Customer Feedback and Market Monitoring 25

DISEASE OVERVIEW 26

  • 2.1 BASIC ANATOMY 26
  • 2.2 DISEASE TREATMENTS AND DIAGNOSTICS 28
    • 2.2.1 General Diagnostics 28
    • 2.2.2 Coronary Artery Disease (CAD) 28
    • 2.2.3 Myocardial Infarction (MI) 29
    • 2.2.4 Angina Pectoris 30
  • 2.3 PATIENT DEMOGRAPHICS 31
    • 2.3.1 General Statistics 31

PRODUCT ASSESSMENT 33

  • 3.1 PRODUCT PORTFOLIOS 33
    • 3.1.1 Coronary Vascular Closure Device Market 33
  • 3.2 REGULATORY ISSUES AND RECALLS 36
    • 3.2.1 Boston Scientific 36
      • 3.2.1.1 Coronary Stent 36
      • 3.2.1.2 PTCA Balloon Catheter 36
      • 3.2.1.3 Interventional Coronary Catheters and Guidewires 37
      • 3.2.1.4 Coronary Embolic Protection Device 38
    • 3.2.2 Cardinal Health 38
      • 3.2.2.1 Coronary Vascular Closure Device 38
    • 3.2.3 Cook Medical 39
      • 3.2.3.1 Coronary Stent 39
      • 3.2.3.2 Interventional Coronary Catheters and Guidewires 39
    • 3.2.4 Cordis (Cardinal Health) 40
      • 3.2.4.1 PTCA Balloon Catheter/Dilation Catheters 40
      • 3.2.4.2 Interventional Coronary Catheters and Guidewires 41
    • 3.2.5 Medtronic 42
      • 3.2.5.1 Coronary Stent 42
      • 3.2.5.2 PTCA Balloon and Dilation Catheters 42
      • 3.2.5.3 Interventional Coronary Catheters and Guidewires 43
    • 3.2.6 Merit Medical Systems 46
      • 3.2.6.1 Interventional Coronary Catheters and Guidewires 46
      • 3.2.6.2 Coronary Introducer Sheath 48
    • 3.2.7 Spectranetics 49
      • 3.2.7.1 Coronary Atherectomy Device 49
    • 3.2.8 St. Jude Medical (Abbott Laboratories) 50
      • 3.2.8.1 Coronary Vascular Closure Device 50
      • 3.2.8.2 Interventional Coronary Catheters and Guidewires 50
    • 3.2.9 Vascular Solutions (Teleflex) 51
      • 3.2.9.1 Interventional Coronary Catheters and Guidewires 51
    • 3.2.10 Volcano Therapeutics (Philips Volcano) 52
      • 3.2.10.1 Interventional Coronary Catheters and Guidewires 52
      • 3.2.10.2 Intravascular Ultrasound (IVUS) Catheter 52
    • 3.2.11 Other Companies 53
      • 3.2.11.1 Coronary Stent and other Vascular Stents 53
      • 3.2.11.2 PTCA balloon catheter 53
      • 3.2.11.3 Interventional Coronary Catheters and Guidewires 54
      • 3.2.11.4 Coronary Atherectomy Device 56
      • 3.2.11.5 Coronary Introducer Sheath 57
      • 3.2.11.6 Intravascular Ultrasound (IVUS) Catheter 57
  • 3.3 CLINICAL TRIALS 58
    • 3.3.1 Abbott Laboratories 58
      • 3.3.1.1 Coronary Stent 58
    • 3.3.2 Asahi Intecc 67
      • 3.3.2.1 Interventional Coronary Catheters and Guidewires 67
    • 3.3.3 B. Braun 68
      • 3.3.3.1 Coronary Stent 68
      • 3.3.3.2 PTCA balloon catheter 69
    • 3.3.4 Biosensors 73
      • 3.3.4.1 Coronary Stent 73
    • 3.3.5 Biotronik 75
      • 3.3.5.1 Coronary Stent 75
      • 3.3.5.2 PTCA balloon catheter 78
    • 3.3.6 Boston Scientific 79
      • 3.3.6.1 Coronary Stent 79
      • 3.3.6.3 PTCA balloon catheter 82
      • 3.3.6.4 Coronary Embolic Protection Device 82
    • 3.3.7 Medtronic 83
      • 3.3.7.1 Coronary Stent 83
      • 3.3.7.2 Interventional Coronary Catheters and Guidewires 86
      • 3.3.7.3 Coronary Embolic Protection Device 87
    • 3.3.8 St. Jude Medical (Abbott Laboratories) 88
      • 3.3.8.1 Interventional Coronary Catheters and Guidewires 88
      • 3.3.8.2 Intravascular Ultrasound (IVUS) Catheter 88
      • 3.3.8.3 Optical Coherence Tomography Catheter 89
      • 3.3.8.4 Fractional Flow Reverse (FFR) Catheter 89
    • 3.3.9 Terumo Interventional Systems (TIS) 90
      • 3.3.9.1 Interventional Coronary Catheters and Guidewires 90
      • 3.3.9.2 Coronary Embolic Protection Device 90
    • 3.3.10 Other Companies 91
      • 3.3.10.1 Coronary Stent 91
      • 3.3.10.2 PTCA balloon catheter 103
      • 3.3.10.3 Interventional Coronary Catheters and Guidewires 104
      • 3.3.10.4 Coronary Embolic Protection Device 107
      • 3.3.10.5 Coronary Chronic Total Occlusion Crosser CTO 108
      • 3.3.10.7 Fractional Flow Reserve (FFR) Guidewire 109
      • 3.3.10.8 Optical Coherence Tomography (OCT) Guidewire 109

CORONARY VASCULAR CLOSURE DEVICE MARKET 111

  • 4.1 INTRODUCTION 111
  • 4.2 MARKET ANALYSIS AND FORECAST 112
  • 4.3 DRIVERS AND LIMITERS 114
    • 4.3.1 Market Drivers 114
    • 4.3.2 Market Limiters 114
  • 4.4 COMPETITIVE MARKET SHARE ANALYSIS 116

ABBREVIATIONS 119

APPENDIX: COMPANY PRESS RELEASES 121

LIST OF CHARTS

  • Chart 1 1: Interventional Cardiology Market by Segment, Japan, 2014 - 2024 3
  • Chart 1 2: Interventional Cardiology Market Overview, Japan, 2017 & 2024 3
  • Chart 4 1: Coronary Vascular Closure Device Market, Japan, 2014 - 2024 113
  • Chart 4 2: Leading Competitors, Coronary Vascular Closure Device Market, Japan, 2017 118

LIST OF FIGURES

  • Figure 1 1: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (1 of 2) 4
  • Figure 1 2: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (2 of 2) 5
  • Figure 1 3: Companies Researched in this Report, Japan, 2017 6
  • Figure 1 4: Factors Impacting the Interventional Cardiology Market by Segment, Japan (1 of 2) 7
  • Figure 1 5: Factors Impacting the Interventional Cardiology Market by Segment, Japan (2 of 2) 8
  • Figure 1 6: Recent Events in the Interventional Cardiology Market, Japan, 2014 - 2017 9
  • Figure 1 7: Interventional Cardiology Markets Covered, Japan, 2017 10
  • Figure 1 8: Interventional Cardiology Procedures Covered, Japan, 2017 11
  • Figure 1 9: Version History 11
  • Figure 3 1: Coronary Vascular Closure Products by Company 35
  • Figure 3 2: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 36
  • Figure 3 3: Class 2 Device Recall Boston Scientific, Small Peripheral Cutting BalloonTM 36
  • Figure 3 4: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 36
  • Figure 3 5: Class 2 Device Recall Boston Scientific ACUITY Pro Coronary Sinus Guide Catheter 37
  • Figure 3 6: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 37
  • Figure 3 7: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 37
  • Figure 3 8: Class 1 Device Recall RotaWire Elite and sireClip Torquer, Guidewire and Guidewire Manipulation Device, Floppy 38
  • Figure 3 9: Class 2 Device Recall MynxGrip Vascular Closure Device 38
  • Figure 3 10: Class 2 Device Recall Zilver 518RX Vascular Stent 39
  • Figure 3 11: Class 2 Device Recall Zilver 518 Vascular Self Expanding Stent 39
  • Figure 3 12: Class 2 Device Recall White Lumax Guiding Coaxial Catheter 39
  • Figure 3 13: Class 2 Device Recall Cordis POWERFLEX PRO PTA Dilatation Catheter 40
  • Figure 3 14: Class 2 Device Recall EMPIRA ? NC RX PTCA Dilatation Catheter 40
  • Figure 3 15: Class 2 Device Recall Cordis EMPIRA RX PTCA Dilatation Catheter 40
  • Figure 3 16: Class 2 Device Recall Cordis ADROIT 6F Guiding Catheter 41
  • Figure 3 17: Class 2 Device Recall Resolute Integrity Zotarolimuseluting Coronary Stent 42
  • Figure 3 18: Class 2 Device Recall PowerCross .018 OTW PTA Dilation Catheter 42
  • Figure 3 19: Class 2 Device Recall Ev3, Inc. (Medtronic) 42
  • Figure 3 20: Class 2 Device Recall NC Sprinter; Rapid Exchange Balloon Dilatation Catheter 43
  • Figure 3 21: Class 2 Device Recall Medtronic Launcher Coronary Guide Catheter 43
  • Figure 3 22: Class 2 Device Recall Launcher Coronary Guiding Catheter 43
  • Figure 3 23: Class 1 Device Recall ZINGER Steerable Guidewire 43
  • Figure 3 24: Class 1 Device Recall Cougar Nitinol Workhorse Guidewire 44
  • Figure 3 25: Class 1 Device Recall COUGAR Steerable Guidewire 44
  • Figure 3 26: Class 1 Device Recall THUNDER Steerable Guidewire 44
  • Figure 3 27: Class 1 Device Recall ProVia CROSSING GUIDEWIRE 44
  • Figure 3 28: Class 1 Device Recall ATTAIN HYBRID Guide Wire 45
  • Figure 3 29: Class 2 Device Recall Medtronic Zuma Guide Catheter 45
  • Figure 3 30: Class 2 Device Recall Merit Maestro Microcatheter 46
  • Figure 3 31: Class 2 Device Recall Merit Laureate Hydrophilic Guide Wire 46
  • Figure 3 32: Class 2 Device Recall Maestro Microcatheter, Merit Medical System 46
  • Figure 3 33: Class 2 Device Recall Performa Cardiac Multipack Catheter 47
  • Figure 3 34: Class 2 Device Recall Hydrophylic guidewire 47
  • Figure 3 35: Class 2 Device Recall PreludeEASE 48
  • Figure 3 36: Class 2 Device Recall Prelude Pro Sheath Introducter 48
  • Figure 3 37: Class 2 Device Recall Turbo Elite Atherectomy Catheter 49
  • Figure 3 38: Class 2 Device Recall ELCA Coronary Atherectomy Catheter 49
  • Figure 3 39: Class 2 Device Recall Vascular closure device 50
  • Figure 3 40: Class 3 Device Recall FastCath" Transseptal Guiding Introducer 50
  • Figure 3 41: Class 1 Device Recall TwinPass Dual Access Catheter 51
  • Figure 3 42: Class 2 Device Recall Percutaneous Catheter 51
  • Figure 3 43: Class 2 Device Recall Prestige Plus Wire 52
  • Figure 3 44: Class 2 Device Recall Volcano s5, s5i, CORE and CORE Mobile systems 52
  • Figure 3 45: Class 2 Device Recall Intravascular Ultrasound System 52
  • Figure 3 46: Class 2 Device Recall FLAIR Endovascular Stent Graft, Bard Peripheral Vascular 53
  • Figure 3 47: Class 1 Device Recall LifeStent Solo Vascular Stent, Bard Peripheral Vascular 53
  • Figure 3 48: Class 2 Device Recall PTA Balloon Dilatation Catheters 53
  • Figure 3 49: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc. 54
  • Figure 3 50: Class 2 Device Recall Coronary Artery Perfusion Cannula with Balloon, Sorin Group USA, Inc. 54
  • Figure 3 51: Class 2 Device Recall Aortic Arch Cannula, Sorin Group USA, Inc. 54
  • Figure 3 52: Class 2 Device Recall Mallinckrodt Launcher Guiding Catheter, Stryker Sustainability Solutions 54
  • Figure 3 53: Class 2 Device Recall Distal Access Catheter (DAC), Concentric Medical Inc 55
  • Figure 3 54: Class 2 Device Recall Distal Access Catheter 55
  • Figure 3 55: Class 2 Device Recall Proplege Coronary Sinus Catheter, Edwards Lifesciences, LLC 55
  • Figure 3 56: Class 2 Device Recall Turbo Elite, ELCA Atherectomy Catheter, Spectranetics Corporation 56
  • Figure 3 57: Class 1 Device Recall Diamondback 360 Coronary Orbital Artherctomy System, Cardiovascular Systems, Inc. 56
  • Figure 3 58: Class 3 Device Recall Diamondback 360 Coronary Orbital Atherectomy System 56
  • Figure 3 59: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc 57
  • Figure 3 60: Class 1 Device Recall Halo One ThinWalled Guiding Sheath, Bard Peripheral Vascular 57
  • Figure 3 61: Class 2 Device Recall SOUNDSTAR eco Catheter, Biosense Webster, Inc. 57
  • Figure 3 62: XIENCE Xpedition/Alpine in Routine Clinical Practice (IRIS XPEDITION) 58
  • Figure 3 63: Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC) 58
  • Figure 3 64: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 59
  • Figure 3 65: Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE) 59
  • Figure 3 66: XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS) 60
  • Figure 3 67: Absorb IV Randomized Controlled Trial 60
  • Figure 3 68: Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA) 61
  • Figure 3 69: Xience Versus Synergy in Left Main PCI (IDEAL-LM) 61
  • Figure 3 70: Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) 62
  • Figure 3 71: XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS) 62
  • Figure 3 72: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (XP China SAS) 63
  • Figure 3 73: A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA) 63
  • Figure 3 74: AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population (ABSORB JAPAN) 64
  • Figure 3 75: XIENCE PRIME Japan Post-Marketing Surveillance (PMS) 64
  • Figure 3 76: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent, Performance, and Technique in Chronic Total Occlusions 65
  • Figure 3 77: Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE (PATRIOT) 65
  • Figure 3 78: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V) 66
  • Figure 3 79: Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (RESTORE) 66
  • Figure 3 80: The Asahi Intecc PTCA Chronic Total Occlusion Study (CTO-PCI) 67
  • Figure 3 81: Optilene® Suture for Coronary Artery Bypass Graft Surgery (OPTICABG) 68
  • Figure 3 82: Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent 68
  • Figure 3 83: Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients (PEPCAD IV) 69
  • Figure 3 84: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) 69
  • Figure 3 85: Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions (PEPCAD V) 70
  • Figure 3 86: The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations (PEPCAD-BIF) 70
  • Figure 3 87: INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent (INDICOR) 71
  • Figure 3 88: A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD) 71
  • Figure 3 89: The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO) 72
  • Figure 3 90: PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel 72
  • Figure 3 91: LEADERS FREE II: BioFreedom™ Pivotal Study 73
  • Figure 3 92: BioFreedom US IDE Feasibility Trial 73
  • Figure 3 93: A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free) 74
  • Figure 3 94: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease (ABSORB-LONG) 75
  • Figure 3 95: BIOTRONIK Orsiro Pre-Marketing Registration (BIOFLOW-VI) 75
  • Figure 3 96: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions 76
  • Figure 3 97: BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite 76
  • Figure 3 98: BIOHELIX-I Bare Metal Stent Study (BIOHELIX-I) 77
  • Figure 3 99: BIOFLOW III Asia Registry 77
  • Figure 3 100: BIOFLOW-III Israel Satellite Registry 77
  • Figure 3 101: Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT (REMEDEE-OCT) 78
  • Figure 3 102: Drug Eluting Pantera Lux Catheter Registry 78
  • Figure 3 103: Post-Approval Study of PROMUS Element™ in China (PEChina) 79
  • Figure 3 104: EVOLVE China Clinical Trial (EVOLVE China) 79
  • Figure 3 105: EVOLVE Short DAPT Study 80
  • Figure 3 106: PROMUS Element Plus US Post-Approval Study 80
  • Figure 3 107: The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) 81
  • Figure 3 108: SYNERGY China: Assess SYNERGY Stent in China 81
  • Figure 3 109: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter 82
  • Figure 3 110: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation 82
  • Figure 3 111: Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions 83
  • Figure 3 112: RESOLUTE ONYX Post-Approval Study (ONYX PAS) 83
  • Figure 3 113: Medtronic RevElution Trial (RevElution) 84
  • Figure 3 114: The European Bifurcation Club Left Main Study (EBC MAIN) 84
  • Figure 3 115: Medtronic Resolute Onyx 2.0 mm Clinical Study 84
  • Figure 3 116: Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study 85
  • Figure 3 117: Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY) 85
  • Figure 3 118: An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (RI-US) 86
  • Figure 3 119: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 86
  • Figure 3 120: Atrial Fibrillation Detected by Continuous ECG Monitoring (LOOP) 87
  • Figure 3 121: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) 88
  • Figure 3 122: ILUMIEN III: OPTIMIZE PCI 88
  • Figure 3 123: ILUMIEN III: OPTIMIZE PCI 89
  • Figure 3 124: Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease (POST-IT) 89
  • Figure 3 125: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 90
  • Figure 3 126: Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis 90
  • Figure 3 127: Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s) 91
  • Figure 3 128: Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) 91
  • Figure 3 129: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 92
  • Figure 3 130: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR) 92
  • Figure 3 131: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 93
  • Figure 3 132: BIONICS - Pharmacokinetics (PK) Trial (BIONICS) 93
  • Figure 3 133: Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT II) 93
  • Figure 3 134: Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 ) 94
  • Figure 3 135: Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease (Firehawk_38) 94
  • Figure 3 136: Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II) 95
  • Figure 3 137: Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT) 95
  • Figure 3 138: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II), Reva Medical 95
  • Figure 3 139: Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I) (FANTOM I), Reva Medical 96
  • Figure 3 140: NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial 96
  • Figure 3 141: A Prospective, Single-arm, Multi-centre, Observational, Real World Registry (Morpheus) 97
  • Figure 3 142: Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II) 97
  • Figure 3 143: First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis 98
  • Figure 3 144: eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries (eTRYTONLM) 98
  • Figure 3 145: An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial (MeriT-II) 99
  • Figure 3 146: An BioMime Vs. Xience Randomised Control Clinical Study (meriT-V) 99
  • Figure 3 147: BIONICS Israel Trial 100
  • Figure 3 148: Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System 100
  • Figure 3 149: Sapphire II PRO US Clinical Study 101
  • Figure 3 150: Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM) 101
  • Figure 3 151: Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I) 101
  • Figure 3 152: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 102
  • Figure 3 153: Procedural Advantages of a Novel Drug-Eluting Coronary Stent 102
  • Figure 3 154: Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study 103
  • Figure 3 155: Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) 103
  • Figure 3 156: Drug Eluting Balloon for Prevention of Constrictive Remodeling 104
  • Figure 3 157: Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis 104
  • Figure 3 158: Real-time MRI Right Heart Catheterization Using Passive Catheters 105
  • Figure 3 159: A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions 105
  • Figure 3 160: Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI (RAPID) 106
  • Figure 3 161: A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter 106
  • Figure 3 162: Performance of the CARDIOGARD Cannula (GECG) 107
  • Figure 3 163: DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR 107
  • Figure 3 164: Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft 108
  • Figure 3 165: Coherex WAVECREST I Left Atrial Appendage Occlusion Study 108
  • Figure 3 166: Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter 109
  • Figure 3 167: Prospective Randomized Optical Coherence Tomography Oslo tRial (PROCTOR) 109
  • Figure 3 168: Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation (OCTACS) 110
  • Figure 4 1: Coronary Vascular Closure Device Market, Japan, 2014 - 2024 112
  • Figure 4 2: Drivers and Limiters, Coronary Vascular Closure Device Market, Japan, 2017 115
  • Figure 4 3: Leading Competitors, Coronary Vascular Closure Device Market, Japan, 2017 117
  • Figure 6 1: Press Release Summary 121
Back to Top